Ross D D, Gao Y, Yang W, Leszyk J, Shively J, Doyle L A
Greenebaum Cancer Center of the University of Maryland and the Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Cancer Res. 1997 Dec 15;57(24):5460-4.
Human breast carcinoma MCF-7/AdrVp cells display a novel multidrug resistance phenotype that is characterized by the overexpression of a 95-kDa membrane glycoprotein (p95) and by marked reduction in intracellular anthracycline accumulation, without overexpression of P-glycoprotein or the multidrug resistance protein MRP. p95 is also highly expressed in multidrug-resistant NCI-H1688 cells derived from a human small cell lung carcinoma. Deglycoslyated p95 from NCI-H1688 cells was isolated by two-dimensional gel electrophoresis and then digested with trypsin. The tryptic peptides were analyzed by mass spectrometry and microsequencing. These analyses identified p95 to be identical to NCA-90, the nonspecific cross-reacting antigen related to the carcinoembryonic antigen (CEA). Further confirmation that p95 is indeed NCA-90 was obtained by Northern and Western blot studies using probes or antibodies specific for p95, NCA-90, or CEA family members. Western blot studies also revealed that CEA itself is overexpressed in MCF-7/AdrVp cells compared to parental MCF-7/W cells. The enforced expression of NCA-90 protein in HeLa cells stably transfected with NCA-90 cDNA did not result in increased resistance of the transfected cells to daunorubicin or a decrease in daunorubicin accumulation in the transfected cells compared to cells transfected only with the expression vector. However, a recent report by H. Kawaharata et al. (Int. J. Cancer, 72: 377-382, 1997) of diminished accumulation, retention, and cytotoxicity of doxorubicin in EJNIH3T3 cells in which enforced expression of CEA was accomplished leaves open the possibility that the overexpression of CEA, possibly in combination with that of NCA-90, could account at least in part for the drug resistant phenotype displayed by MCF-7/AdrVp cells.
人乳腺癌MCF-7/AdrVp细胞呈现出一种新的多药耐药表型,其特征是一种95 kDa膜糖蛋白(p95)过表达,细胞内蒽环类药物蓄积显著减少,且P-糖蛋白或多药耐药蛋白MRP无过表达。p95在源自人小细胞肺癌的多药耐药NCI-H1688细胞中也高度表达。通过二维凝胶电泳分离出NCI-H1688细胞去糖基化的p95,然后用胰蛋白酶消化。对胰蛋白酶消化后的肽段进行质谱分析和微量测序。这些分析确定p95与NCA-90相同,NCA-90是与癌胚抗原(CEA)相关的非特异性交叉反应抗原。使用针对p95、NCA-90或CEA家族成员的探针或抗体进行Northern和Western印迹研究,进一步证实p95确实是NCA-90。Western印迹研究还显示,与亲本MCF-7/W细胞相比,CEA本身在MCF-7/AdrVp细胞中过表达。用NCA-90 cDNA稳定转染的HeLa细胞中NCA-90蛋白的强制表达,与仅用表达载体转染的细胞相比,并未导致转染细胞对柔红霉素的耐药性增加或柔红霉素在转染细胞中的蓄积减少。然而,H. Kawaharata等人(《国际癌症杂志》,72: 377 - 382, 1997)最近的一份报告指出,在强制表达CEA的EJNIH3T3细胞中,阿霉素的蓄积、滞留和细胞毒性降低,这使得CEA过表达(可能与NCA-90过表达共同作用)至少部分解释MCF-7/AdrVp细胞所表现出的耐药表型成为可能。